Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis

Elif Emirogullari; Cetin Saatci; Aydin Unal; Atilla Sahin; Yusuf Ozkul1

Nephro-Urology Monthly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis

Author(s):

Elif Funda Emirogullari^1,*,

Cetin Saatci²,

Aydin Unal²,

Atilla Sahin²,

Yusuf Ozkul1²

1Erciyes University, Medical Faculty, Department of Medical Genetics, eliffunda@erciyes.edu.tr, TURKEY

2Department of Medical Genetics, Erciyes University Medical School, Turkey

Nephro-Urology Monthly:Vol. 2, issue 2; 314-319

Article type:Research Article

Received:Jul 08, 2009

Accepted:Aug 27, 2009

How to Cite:Elif Funda EmirogullariCetin SaatciAydin UnalAtilla SahinYusuf Ozkul1Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis.Nephro-Urol Mon.2(2):314-319.

Abstract

Background and Aims: Factor V Leiden mutation (G1691A) has been recognized to be the most prevalent genetic risk factor for venous thrombosis. Other common risk factor for venous thrombosis is Prothrombin 20210 G-A alteration, which causes a gain of function in the coagulation system with an increase of prothrombin levels, associated with an increased potential to form thrombin. Plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism is the most frequently studied in thrombotic events. Aim of this study was to investigate the relationship between these polymorphisms and arteriovenous fistula (AVF) thrombosis in hemodialysis (HD) patients.

Methods: The study included 31 HD patients with AVF thrombosis and 51 HD patients without AVF thrombosis. DNA was extracted from peripheral blood samples from the patient and control groups. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods were used to identify the polymorphisms.

Results: There were no significant differences between HD patients with and without AVF thrombosis in terms of Factor V Leiden and Prothrombin G20210A mutations. PAI-1 4G allele in heterozygous state have an effect on the thrombosis risk in HD patients (O.R= 4.271).

Conclusions: Only carrying PAI-1 4G/5G genotype had an additional risk for thrombosis in HD patients.

Keywords

Hemodialysis

Factor V Leiden mutation

Plasminogen Activator Inhibitor Type 1 4G/5G Polymorphism

Prothrombin G20210A Mutation

Full Text

Full text is available in PDF

comments